Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor? inhibition of lymphokine-activated killer cell generation
- 1 March 1993
- journal article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 119 (3) , 131-136
- https://doi.org/10.1007/bf01229526
Abstract
After simultaneous stimulation with anti-CD3 monoclonal antibody (mAb) at 10 ng/ml, anti-CD28 mAb at 125 ng/ml, and interleukin-2 (IL-2) at 20 U/ml, peripheral blood mononuclear cells (PBMC) were partially resistant to immunosuppression by transforming growth factor-β (TGFβ2). The doses of TGFβ2 that inhibit cytotoxicity of IL-2 stimulated cells by 60%–70% were much less effective when the same cells were stimulated with anti-CD3/anti-CD28/IL-2. This favorable stimulation generated a cell population characterized by high lytic activity, excellent expansion, and a greater resistance to immunosuppressive action of TGFβ2. The secretion of secondary cytokines important for LAK generation is considered a crucial event, at least partially responsible for the antagonization of TGFβ immunosuppression.Keywords
This publication has 40 references indexed in Scilit:
- Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: Growth characteristics, cytolytic activity, and cell phenotypeCancer Immunology, Immunotherapy, 1991
- Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factorCancer Immunology, Immunotherapy, 1991
- Do CD2 and CD3-TCR T-cell activation pathways function independently?Immunology Today, 1990
- Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodiesCancer Immunology, Immunotherapy, 1990
- Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancerCancer Immunology, Immunotherapy, 1990
- Role of the CD28 receptor in T-cell activationImmunology Today, 1990
- The role of CD4 in T-cell activation: accessory molecule or co-receptor?Immunology Today, 1989
- Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytesJournal of Autoimmunity, 1989
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987